Colorectal Cancer News and Research RSS Feed - Colorectal Cancer News and Research

Colorectal Cancer is cancer that develops in the colon (the longest part of the large intestine) and/or the rectum (the last several inches of the large intestine before the anus). In the United States, it is the fourth most common cancer in men and women. Caught early, it is often curable.
University of Bradford researchers devise simple blood test to diagnose cancer

University of Bradford researchers devise simple blood test to diagnose cancer

Researchers from the University of Bradford, UK, have devised a simple blood test that can be used to diagnose whether people have cancer or not. [More]
Scientists find high proportion of oral bacteria in gut microbiota of liver cirrhosis patients

Scientists find high proportion of oral bacteria in gut microbiota of liver cirrhosis patients

Scientists from INRA in collaboration with a Chinese team found that the gut microbiota[1] of individuals with liver cirrhosis differ notably from healthy individuals', showing a high proportion of oral bacteria. [More]
Vanderbilt-led research team identifies protein "signatures" that drive colorectal cancer

Vanderbilt-led research team identifies protein "signatures" that drive colorectal cancer

A Vanderbilt University-led research team has identified protein "signatures" of genetic mutations that drive colorectal cancer, the nation's second leading cause of cancer deaths after lung cancer. [More]
Researchers propose ‘microbiome cloud model’ to understand variation in individual's microbiome composition

Researchers propose ‘microbiome cloud model’ to understand variation in individual's microbiome composition

The Human Microbiome Project (HMP) is a global initiative to identify and characterize the microorganisms present at multiple sites in the human body. [More]
Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation. [More]
Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

The basic idea of cancer chemopre­vention is to arrest or reverse the progression of pre­malignant cells towards full malignancy, using physiological mechanisms that do not kill healthy cells. [More]
Dmitry Medvedev presents Russia's first national "Industry" award to BIOCAD

Dmitry Medvedev presents Russia's first national "Industry" award to BIOCAD

On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company BIOCAD. [More]
Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema. [More]
Aspirin, smoking influence aging processes of female genome connected to colorectal cancer

Aspirin, smoking influence aging processes of female genome connected to colorectal cancer

The risk of developing cancer increases with age. Factors like smoking and regular aspirin use also affect the risk of cancer - although in the opposite sense. Researchers from the University of Basel were now able to show that aspirin use and smoking both influence aging processes of the female genome that are connected to colorectal cancer. [More]
HIV-positive people with early-stage cancer less likely to get cancer treatment

HIV-positive people with early-stage cancer less likely to get cancer treatment

HIV-infected people diagnosed with cancer are two to four times more likely to go untreated for their cancer compared to uninfected cancer patients, according to a new, large retrospective study from researchers in Penn Medicine's Abramson Cancer Center and the National Cancer Institute (NCI) published online ahead of print in the Journal of Clinical Oncology. [More]
Phase III TAS-102 study for metastatic colorectal cancer shows improved survival

Phase III TAS-102 study for metastatic colorectal cancer shows improved survival

The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. [More]
patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. [More]
Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), announced today detailed findings from its global Phase III RECOURSE trial of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug. [More]
Study identifies genetics as dominant risk factor in breast, prostate and colorectal cancers

Study identifies genetics as dominant risk factor in breast, prostate and colorectal cancers

A study of individuals who have been adopted has identified genetics as the dominant risk factor in 'familial' breast, prostate and colorectal cancers. [More]
Gene partnership may be fueling cancer spread in as much as 20% of cancers

Gene partnership may be fueling cancer spread in as much as 20% of cancers

A key cancer-causing gene, responsible for up to 20 percent of cancers, may have a weak spot in its armor, according to new research from the Masonic Cancer Center, University of Minnesota. [More]
Small antioxidant molecules suppress colon cancer associated with colitis

Small antioxidant molecules suppress colon cancer associated with colitis

Researchers from Case Western Reserve and Dartmouth universities have shown that a class of small antioxidant molecules carries enormous promise for supressing colon cancer associated with colitis. [More]
Colon has safety mechanism to restrict formation and growth of adenomas

Colon has safety mechanism to restrict formation and growth of adenomas

Colon cancer development starts with the formation of benign tumours called adenomas. It is estimated that between 30% and 50% of people over 50 will develop one of these tumours. [More]
Research roundup: Improving colon cancer screening; disparities in heart care; Medicaid expansion's effect on cities

Research roundup: Improving colon cancer screening; disparities in heart care; Medicaid expansion's effect on cities

This report estimated the effect of the Affordable Care Act (ACA) on 14 large and diverse cities: Los Angeles, Chicago, Houston, Philadelphia, Phoenix, Indianapolis, Columbus, Charlotte, Detroit, Memphis, Seattle, Denver, Atlanta, and Miami. [More]
UEG calls for more nurse endoscopy workforce to reduce CRC deaths

UEG calls for more nurse endoscopy workforce to reduce CRC deaths

Colorectal cancer (CRC) is currently estimated to claim the lives of 214,675[1] adults in Europe, equivalent to 1 death every 3 minutes. [More]
Promising way to prevent disparities in colorectal cancer screening

Promising way to prevent disparities in colorectal cancer screening

People living in poverty are less likely to be screened regularly for colorectal cancer-and more likely to develop the disease and die from it. How to end these disparities-and raise screening rates, lower disease rates, and prevent deaths? A promising way is to mail fecal immunochemical tests (a newer kind of stool test) to populations, Beverly B. Green, MD, MPH, and Gloria D. Coronado, PhD, wrote in the June 17 JAMA Internal Medicine. [More]